ASPIRIN; MEPROBAMATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for aspirin; meprobamate and what is the scope of freedom to operate?
Aspirin; meprobamate
is the generic ingredient in five branded drugs marketed by Sun Pharm Industries, Sandoz, Par Pharm, Medpointe Pharm Hlc, and Quantum Pharmics, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.Summary for ASPIRIN; MEPROBAMATE
| US Patents: | 0 |
| Tradenames: | 5 |
| Applicants: | 5 |
| NDAs: | 5 |
| DailyMed Link: | ASPIRIN; MEPROBAMATE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ASPIRIN; MEPROBAMATE
US Patents and Regulatory Information for ASPIRIN; MEPROBAMATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | MEPRO-ASPIRIN | aspirin; meprobamate | TABLET;ORAL | 089127-001 | Mar 2, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medpointe Pharm Hlc | MICRAININ | aspirin; meprobamate | TABLET;ORAL | 084978-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Par Pharm | MEPROBAMATE AND ASPIRIN | aspirin; meprobamate | TABLET;ORAL | 089126-001 | Aug 19, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Quantum Pharmics | Q-GESIC | aspirin; meprobamate | TABLET;ORAL | 088740-001 | Jun 1, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm Industries | EQUAGESIC | aspirin; meprobamate | TABLET;ORAL | 011702-003 | Dec 29, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
